TKT Replagal Renal Function Trial To Be Submitted By Year-End

Transkaryotic Therapies will submit data from a Phase III trial evaluating renal function in Fabry disease patients treated with Replagal by the end of the year, CEO Richard Selden, MD/PhD, said Oct. 30

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet